Biogen Inc Stock Beta
| BIIB34 Stock | BRL 154.95 1.20 0.78% |
Biogen Inc fundamentals help investors to digest information that contributes to Biogen's financial success or failures. It also enables traders to predict the movement of Biogen Stock. The fundamental analysis module provides a way to measure Biogen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biogen stock.
Biogen |
Biogen Inc Company Beta Analysis
Biogen's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Biogen Beta | 0.22 |
Most of Biogen's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biogen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Biogen Inc has a Beta of 0.2235. This is 74.01% lower than that of the Healthcare sector and 80.9% lower than that of the Drug Manufacturers - Major industry. The beta for all Brazil stocks is notably lower than that of the firm.
Biogen Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biogen's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biogen could also be used in its relative valuation, which is a method of valuing Biogen by comparing valuation metrics of similar companies.Biogen is currently under evaluation in beta category among its peers.
As returns on the market increase, Biogen's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biogen is expected to be smaller as well.
Biogen Fundamentals
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 230.79 B | |||
| Shares Outstanding | 867.48 M | |||
| Price To Earning | 6.38 X | |||
| Price To Book | 3.28 X | |||
| Price To Sales | 21.53 X | |||
| Revenue | 10.98 B | |||
| Gross Profit | 8.87 B | |||
| EBITDA | 2.88 B | |||
| Net Income | 1.56 B | |||
| Cash And Equivalents | 3.91 B | |||
| Cash Per Share | 20.16 X | |||
| Total Debt | 6.27 B | |||
| Debt To Equity | 46.10 % | |||
| Current Ratio | 2.84 X | |||
| Book Value Per Share | 14.82 X | |||
| Cash Flow From Operations | 3.64 B | |||
| Earnings Per Share | 16.90 X | |||
| Price To Earnings To Growth | 36.44 X | |||
| Number Of Employees | 9.61 K | |||
| Beta | 0.22 | |||
| Market Capitalization | 218.2 B | |||
| Total Asset | 23.88 B | |||
| Z Score | 20.4 | |||
| Net Asset | 23.88 B |
About Biogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biogen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biogen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Biogen Stock
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.